Fill and finish

Pharmaceutics International, Inc. (Pii) to Platform West Pharmaceutical Services, Inc.’s Daikyo Crystal Zenith® Container-Closure Components for Aseptic Fill-Finish

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical industry, Health sciences, Life sciences, Syringe, Fill and finish, Contract manufacturing organization, Health care

Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.

Key Points: 
  • Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO) will include Daikyo Crystal Zenith (CZ) container-closure components, offered by West Pharmaceutical Services, Inc. (West), as part of its aseptic fill-finish capabilities across vials, syringes and cartridges.
  • Piis initial implementation will be filling ready-to-use (RU) syringes and cartridges in its aseptic fill-finish processes.
  • We are a trusted partner to the worlds top pharmaceutical and biotechnology companiesworking by their side to improve patient health.
  • Crystal Zenith technology is licensed to West Pharmaceutical Services, Inc. from Daikyo Seiko, Ltd.

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

Retrieved on: 
Thursday, July 15, 2021
Mithra, Yazatas, Fill and finish, Economic sectors, Economic taxonomy

ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.

Key Points: 
  • ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.
  • Under the terms of the collaboration, Mithra will be responsible for upscalingand manufacturing services for filling the drug substance in support of clinical and commercial supply.
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility.
  • Renaat Baes, Chief Manufacturing Officer of Mithra, commented:"We are absolutely thrilled to enter into this collaboration agreement with ExeVir, who is developing promising innovative Covid-19 treatments.

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

Retrieved on: 
Thursday, July 15, 2021
Mithra, Yazatas, Fill and finish, Economic sectors, Economic taxonomy

ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.

Key Points: 
  • ExeVir launched less than one year ago and has made tremendous progress in building the company and an innovative pipeline.
  • Under the terms of the collaboration, Mithra will be responsible for upscalingand manufacturing services for filling the drug substance in support of clinical and commercial supply.
  • Torsten Mummenbrauer, CEO of ExeVir Bio, said: "We are very pleased to collaborate with Mithra which has built a cutting-edge new fill and finish manufacturing facility.
  • Renaat Baes, Chief Manufacturing Officer of Mithra, commented:"We are absolutely thrilled to enter into this collaboration agreement with ExeVir, who is developing promising innovative Covid-19 treatments.

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Retrieved on: 
Tuesday, July 13, 2021
Other Manufacturing, Research, Venture capital, Professional services, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Canon law of the Catholic Church, Curia, Fill and finish, Economic sectors, Economic taxonomy, Economy, Curia, Integrity Bio, CURIA, INTEGRITY BIO

Integrity Bios biologic capabilities are complementary with Curias existing business and will enable Curia to expand its ability to meet customers needs.

Key Points: 
  • Integrity Bios biologic capabilities are complementary with Curias existing business and will enable Curia to expand its ability to meet customers needs.
  • Curia has decades of experience in managing complexity from R&D through manufacturing, said Curia Chairman and CEO John Ratliff.
  • As part of Curia, we can now offer our customers not only world-class formulation and fill-finish but also world-class commercial manufacturing.
  • Integrity Bio is a privately owned company focused on providing large molecule formulation and fill/finish services to the biotech and pharmaceutical industries.

Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine

Retrieved on: 
Tuesday, June 1, 2021
Packaging, Health, Infectious diseases, Manufacturing, Genetics, Pharmaceutical, Biotechnology, Medical research, COVID-19 vaccines, Clinical trials, RNA vaccines, Health sciences, Medicine, Health, Moderna COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, Fill and finish, Moderna, Thermo Fisher Scientific

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has entered into an agreement with Thermo Fisher Scientific (NYSE: TMO) for fill/finish sterile manufacturing services and supply packaging for Modernas COVID-19 vaccine.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has entered into an agreement with Thermo Fisher Scientific (NYSE: TMO) for fill/finish sterile manufacturing services and supply packaging for Modernas COVID-19 vaccine.
  • Under the terms of the agreement, Thermo Fishers commercial manufacturing site in Greenville, North Carolina will be used for aseptic fill/finish, labeling and packaging to support the production of hundreds of millions of doses of the Moderna COVID-19 vaccine.
  • Thermo Fisher has been a critical partner in supplying raw materials for our COVID-19 vaccine and we are now pleased to further expand our relationship as an important manufacturing partner as well, said Juan Andres, Modernas Chief Technical Operations and Quality Officer.
  • The addition of Thermo Fisher to our network will support our efforts to scale up our manufacturing ability.

Grand River Aseptic Manufacturing Selected as 2021 Facility of the Year Awards Winner for Special Recognition for Operational Agility: COVID-19 Impact

Retrieved on: 
Wednesday, April 28, 2021
Companies, Grand Rapids, Michigan, Grand River Aseptic Manufacturing, Health care, Life sciences, Johnson & Johnson, Fill and finish

b'GRAND RAPIDS, Mich., April 28, 2021 /PRNewswire/ --Grand River Aseptic Manufacturing ("GRAM"), a leading injectable contract development and manufacturing organization ("CDMO"), was awarded the 2021 Facility of the Year Award for Special Recognition of Operational Agility: COVID-19 by the International Society for Pharmaceutical Engineering (ISPE).

Key Points: 
  • b'GRAND RAPIDS, Mich., April 28, 2021 /PRNewswire/ --Grand River Aseptic Manufacturing ("GRAM"), a leading injectable contract development and manufacturing organization ("CDMO"), was awarded the 2021 Facility of the Year Award for Special Recognition of Operational Agility: COVID-19 by the International Society for Pharmaceutical Engineering (ISPE).
  • ft., world-class, large-scale fill/finish facility in downtown Grand Rapids, Michigan.\nGRAM recognized for design and efficacy of its world-class, large-scale fill/finish facility in Grand Rapids, Michigan\nGRAM designed the fill/finish facility from the ground up with a focus on safety, capacity, and flexibility.
  • Employee safety, exceeding regulatory requirements, and client needs stayed at the forefront by choosing best-in-class technology and facility design solutions first, then building the facility around to support.
  • GRAM sped up operational readiness by six weeks to provide fill/finish services for Johnson & Johnson\'s COVID-19 vaccine at its new facility.

Vaccine Contract Manufacturing Market Size to Reach Revenues of around USD 4 Billion by 2026 - Arizton

Retrieved on: 
Wednesday, April 14, 2021
Articles, Economy, Vaccination, Pharmaceutical industry, Virology, Fill and finish, Manufacturing, Packaging, Outsourcing, Pandemic, Vaccine

There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide.

Key Points: 
  • There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide.
  • 34% in 2020, and they are likely to witness the highest incremental growth of over USD 633 million during the forecast period.
  • Fill/finish services are subject to extreme scrutiny by regulatory agencies and tend to be costly in the manufacturing process.
  • Hence, vaccine manufacturers outsource these services to CMOs, which help them meet unexpected demands, source policies or better matching scales.

Vaccine Contract Manufacturing Market Size to Reach Revenues of around USD 4 Billion by 2026 - Arizton

Retrieved on: 
Wednesday, April 14, 2021
Articles, Economy, Vaccination, Pharmaceutical industry, Virology, Fill and finish, Manufacturing, Packaging, Outsourcing, Pandemic, Vaccine

There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide.

Key Points: 
  • There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide.
  • 34% in 2020, and they are likely to witness the highest incremental growth of over USD 633 million during the forecast period.
  • Fill/finish services are subject to extreme scrutiny by regulatory agencies and tend to be costly in the manufacturing process.
  • Hence, vaccine manufacturers outsource these services to CMOs, which help them meet unexpected demands, source policies or better matching scales.

Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio

Retrieved on: 
Tuesday, April 6, 2021
Science, Stem cells, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical trials, Life sciences, Catalent, Gene therapy, Health sciences, Medicine, Medical research, COVID-19 vaccines, Clinical trials, COVID-19 vaccine, Fill and finish, Draft:John Chiminski, Moderna COVID-19 vaccine, Moderna, Catalent

In June 2020, Catalent and Moderna announced that Catalent would provide aseptic vial filling and packaging from its Bloomington site, including additional staffing required for 24x7 manufacturing to support production of an initial 100 million doses of Modernas vaccine.

Key Points: 
  • In June 2020, Catalent and Moderna announced that Catalent would provide aseptic vial filling and packaging from its Bloomington site, including additional staffing required for 24x7 manufacturing to support production of an initial 100 million doses of Modernas vaccine.
  • We appreciate this expanded collaboration with Catalent and the dedication of their team, said Juan Andres, Modernas Chief Technical Operations and Quality Officer.
  • This additional fill-finish capacity will be important for not only our COVID-19 vaccine, but also potentially for other programs in our clinical development pipeline.
  • Catalent announced in September 2020 its $50 million investment into this third high-speed vial filling line at Bloomington.

Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio

Retrieved on: 
Tuesday, April 6, 2021
Research, Infectious diseases, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Life sciences, Catalent, Gene therapy, Health sciences, Medicine, Medical research, COVID-19 vaccines, Clinical trials, COVID-19 vaccine, Fill and finish, Draft:John Chiminski, Moderna COVID-19 vaccine, Moderna, Catalent

In June 2020, Catalent and Moderna announced that Catalent would provide aseptic vial filling and packaging from its Bloomington site, including additional staffing required for 24x7 manufacturing to support production of an initial 100 million doses of Modernas vaccine.

Key Points: 
  • In June 2020, Catalent and Moderna announced that Catalent would provide aseptic vial filling and packaging from its Bloomington site, including additional staffing required for 24x7 manufacturing to support production of an initial 100 million doses of Modernas vaccine.
  • We appreciate this expanded collaboration with Catalent and the dedication of their team, said Juan Andres, Modernas Chief Technical Operations and Quality Officer.
  • This additional fill-finish capacity will be important for not only our COVID-19 vaccine, but also potentially for other programs in our clinical development pipeline.
  • Catalent announced in September 2020 its $50 million investment into this third high-speed vial filling line at Bloomington.